Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies

<p style="text-align:justify;"> <b>Background:</b> To investigate disease progression the first 12 months after diagnosis in children with type 1 diabetes negative (AAB negative) for pancreatic autoantibodies [islet cell autoantibodies(ICA), glutamic acid decarboxylase a...

Full description

Bibliographic Details
Main Authors: Pörksen, S, Laborie, L, Nielsen, L, Louise Max Andersen, M, Sandal, T, De Wet, H, Schwarcz, E, Aman, J, Swift, P, Kocova, M, Schönle, E, de Beaufort, C, Hougaard, P, Ashcroft, F, Molven, A, Knip, M, Mortensen, H, Hansen, L, Njølstad, P
Format: Journal article
Language:English
Published: BioMed Central 2010
_version_ 1797050252053708800
author Pörksen, S
Laborie, L
Nielsen, L
Louise Max Andersen, M
Sandal, T
De Wet, H
Schwarcz, E
Aman, J
Swift, P
Kocova, M
Schönle, E
de Beaufort, C
Hougaard, P
Ashcroft, F
Molven, A
Knip, M
Mortensen, H
Hansen, L
Njølstad, P
author_facet Pörksen, S
Laborie, L
Nielsen, L
Louise Max Andersen, M
Sandal, T
De Wet, H
Schwarcz, E
Aman, J
Swift, P
Kocova, M
Schönle, E
de Beaufort, C
Hougaard, P
Ashcroft, F
Molven, A
Knip, M
Mortensen, H
Hansen, L
Njølstad, P
author_sort Pörksen, S
collection OXFORD
description <p style="text-align:justify;"> <b>Background:</b> To investigate disease progression the first 12 months after diagnosis in children with type 1 diabetes negative (AAB negative) for pancreatic autoantibodies [islet cell autoantibodies(ICA), glutamic acid decarboxylase antibodies (GADA) and insulinoma-associated antigen-2 antibodies (IA-2A)]. Furthermore the study aimed at determining whether mutations in KCNJ11, ABCC8, HNF1A, HNF4A or INS are common in AAB negative diabetes.<br/><br/> <b>Materials and methods:</b> In 261 newly diagnosed children with type 1 diabetes, we measured residual β-cell function, ICA, GADA, and IA-2A at 1, 6 and 12 months after diagnosis. The genes KCNJ11, ABCC8, HNF1A, HNF4A and INS were sequenced in subjects AAB negative at diagnosis. We expressed recombinant K-ATP channels in Xenopus oocytes to analyse the functional effects of an ABCC8 mutation.<br/><br/> <b>Results:</b> Twenty-four patients (9.1%) tested AAB negative after one month. Patients, who were AAB-negative throughout the 12-month period, had higher residual β-cell function (P = 0.002), lower blood glucose (P = 0.004), received less insulin (P = 0.05) and had lower HbA1c (P = 0.02) 12 months after diagnosis. One patient had a heterozygous mutation leading to the substitution of arginine at residue 1530 of SUR1 (ABCC8) by cysteine. Functional analyses of recombinant K-ATP channels showed that R1530C markedly reduced the sensitivity of the K-ATP channel to inhibition by MgATP. Morover, the channel was highly sensitive to sulphonylureas. However, there was no effect of sulfonylurea treatment after four weeks on 1.0-1.2 mg/kg/24 h glibenclamide.<br/><br/> <b>Conclusion:</b> GAD, IA-2A, and ICA negative children with new onset type 1 diabetes have slower disease progression as assessed by residual beta-cell function and improved glycemic control 12 months after diagnosis. One out of 24 had a mutation in ABCC8, suggesting that screening of ABCC8 should be considered in patients with AAB negative type 1 diabetes. </p>
first_indexed 2024-03-06T18:02:25Z
format Journal article
id oxford-uuid:0042e2d8-e412-4270-8103-5691b55064a8
institution University of Oxford
language English
last_indexed 2024-03-06T18:02:25Z
publishDate 2010
publisher BioMed Central
record_format dspace
spelling oxford-uuid:0042e2d8-e412-4270-8103-5691b55064a82022-03-26T08:28:31ZDisease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 AntibodiesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0042e2d8-e412-4270-8103-5691b55064a8EnglishSymplectic Elements at OxfordBioMed Central2010Pörksen, SLaborie, LNielsen, LLouise Max Andersen, MSandal, TDe Wet, HSchwarcz, EAman, JSwift, PKocova, MSchönle, Ede Beaufort, CHougaard, PAshcroft, FMolven, AKnip, MMortensen, HHansen, LNjølstad, P <p style="text-align:justify;"> <b>Background:</b> To investigate disease progression the first 12 months after diagnosis in children with type 1 diabetes negative (AAB negative) for pancreatic autoantibodies [islet cell autoantibodies(ICA), glutamic acid decarboxylase antibodies (GADA) and insulinoma-associated antigen-2 antibodies (IA-2A)]. Furthermore the study aimed at determining whether mutations in KCNJ11, ABCC8, HNF1A, HNF4A or INS are common in AAB negative diabetes.<br/><br/> <b>Materials and methods:</b> In 261 newly diagnosed children with type 1 diabetes, we measured residual β-cell function, ICA, GADA, and IA-2A at 1, 6 and 12 months after diagnosis. The genes KCNJ11, ABCC8, HNF1A, HNF4A and INS were sequenced in subjects AAB negative at diagnosis. We expressed recombinant K-ATP channels in Xenopus oocytes to analyse the functional effects of an ABCC8 mutation.<br/><br/> <b>Results:</b> Twenty-four patients (9.1%) tested AAB negative after one month. Patients, who were AAB-negative throughout the 12-month period, had higher residual β-cell function (P = 0.002), lower blood glucose (P = 0.004), received less insulin (P = 0.05) and had lower HbA1c (P = 0.02) 12 months after diagnosis. One patient had a heterozygous mutation leading to the substitution of arginine at residue 1530 of SUR1 (ABCC8) by cysteine. Functional analyses of recombinant K-ATP channels showed that R1530C markedly reduced the sensitivity of the K-ATP channel to inhibition by MgATP. Morover, the channel was highly sensitive to sulphonylureas. However, there was no effect of sulfonylurea treatment after four weeks on 1.0-1.2 mg/kg/24 h glibenclamide.<br/><br/> <b>Conclusion:</b> GAD, IA-2A, and ICA negative children with new onset type 1 diabetes have slower disease progression as assessed by residual beta-cell function and improved glycemic control 12 months after diagnosis. One out of 24 had a mutation in ABCC8, suggesting that screening of ABCC8 should be considered in patients with AAB negative type 1 diabetes. </p>
spellingShingle Pörksen, S
Laborie, L
Nielsen, L
Louise Max Andersen, M
Sandal, T
De Wet, H
Schwarcz, E
Aman, J
Swift, P
Kocova, M
Schönle, E
de Beaufort, C
Hougaard, P
Ashcroft, F
Molven, A
Knip, M
Mortensen, H
Hansen, L
Njølstad, P
Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies
title Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies
title_full Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies
title_fullStr Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies
title_full_unstemmed Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies
title_short Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies
title_sort disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ica gad and ia 2 antibodies
work_keys_str_mv AT porksens diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT laboriel diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT nielsenl diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT louisemaxandersenm diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT sandalt diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT deweth diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT schwarcze diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT amanj diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT swiftp diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT kocovam diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT schonlee diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT debeaufortc diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT hougaardp diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT ashcroftf diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT molvena diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT knipm diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT mortensenh diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT hansenl diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies
AT njølstadp diseaseprogressionandsearchformonogenicdiabetesamongchildrenwithnewonsettype1diabetesnegativeforicagadandia2antibodies